Paper Details

  1. Home
  2. Paper Details

Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial.

Author: BhattiLaveeza, BlickGary, BredeekFritz, BrennanRobert, CampbellAndrew L, Da Silva-TillmannBarbara, ElionRichard, EronJoseph J, FredrickLinda, GatheJoseph, GibbonsKrystal, HuYiran B, KhatriAmit, LalezariJay, McGovernBarbara, Pilot-MatiasTami, PodsadeckiThomas, RuanePeter J, SchnellGretja, SlimJihad, SulkowskiMark S, TrinhRoger, TripathiRakesh, WangChia, WylesDavid

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This pilot study assessed the efficacy of an all-oral 3 direct-acting antiviral (3D) regimen for HCV genotype 1 infection in adults co-infected with HIV-1. SVR12 was achieved in 94% of patients treated for 12 weeks and 91% treated for 24 weeks. Adverse events were generally mild and did not lead to discontinuation.
Paper Details　
Original Abstract of the Article :
IMPORTANCE: Patients co-infected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) are at high risk for liver disease progression. However, interferon-based treatments for HCV infection have significant toxicities, limiting treatment uptake. OBJECTIVE: To assess the all-oral 3 dir...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1001/jama.2015.1328

データ提供：米国国立医学図書館（NLM）

Combating Hepatitis C: A New Treatment Regimen for HIV-Co-infected Patients

Hepatitis C virus (HCV) infection is a major global health concern, particularly in individuals co-infected with human immunodeficiency virus (HIV). This article explores the efficacy of a novel all-oral 3 direct-acting antiviral (3D) regimen, consisting of ombitasvir, paritaprevir (co-dosed with ritonavir), dasabuvir, and ribavirin, in treating HCV genotype 1 infection in adults with HIV-1 co-infection. The researchers conducted a randomized, open-label pilot study to assess the effectiveness of this regimen.

A Promising Approach to HCV Treatment

The study found that the 3D plus ribavirin regimen resulted in high sustained virologic response (SVR) rates in HCV genotype 1-infected adults with HIV-1 co-infection, regardless of whether they received 12 or 24 weeks of treatment. The regimen was generally well-tolerated, with few serious adverse events. The researchers emphasize the importance of further phase 3 studies to confirm these findings and to evaluate the long-term effectiveness of this regimen.

Hope for Improved HCV Treatment

This study provides encouraging evidence for the effectiveness of a novel all-oral, interferon-free regimen for HCV infection in HIV-1 co-infected patients. The findings offer hope for improved treatment outcomes and a better quality of life for individuals with this co-infection. Continued research is crucial to confirm the long-term efficacy and safety of this regimen, paving the way for more effective and convenient treatment options.

Dr.Camel's Conclusion

Just as a camel adapts to the harsh desert environment, individuals with HCV infection need to find ways to navigate the challenges of this condition. This study highlights a promising new treatment regimen for HCV in HIV-co-infected patients, offering hope for improved outcomes and enhanced quality of life. It's a reminder that ongoing research and development are essential for finding more effective and tolerable treatments for complex medical conditions.

Date :
  1. Date Completed 2015-04-07
  2. Date Revised 2022-04-08
Further Info :

Pubmed ID

25706092

DOI: Digital Object Identifier

10.1001/jama.2015.1328

Related Literature

Article Analysis
・Effective treatment of hepatitis c
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.